Your browser is no longer supported. Please, upgrade your browser.
Xenetic Biosciences, Inc.
Index- P/E- EPS (ttm)-1.66 Insider Own7.50% Shs Outstand8.75M Perf Week-5.53%
Market Cap21.69M Forward P/E- EPS next Y-0.37 Insider Trans0.00% Shs Float- Perf Month-29.30%
Income-11.20M PEG- EPS next Q-0.12 Inst Own4.20% Short Float- Perf Quarter7.77%
Sales0.70M P/S30.98 EPS this Y73.10% Inst Trans-22.92% Short Ratio0.00 Perf Half Y-4.31%
Book/sh1.14 P/B1.95 EPS next Y32.70% ROA-100.70% Target Price- Perf Year149.44%
Cash/sh0.95 P/C2.33 EPS next 5Y- ROE-109.40% 52W Range0.76 - 5.85 Perf YTD8.82%
Dividend- P/FCF- EPS past 5Y45.40% ROI-90.30% 52W High-62.05% Beta2.56
Dividend %- Quick Ratio10.60 Sales past 5Y- Gross Margin- 52W Low192.11% ATR0.18
Employees4 Current Ratio10.60 Sales Q/Q200.00% Oper. Margin- RSI (14)33.30 Volatility5.68% 5.96%
OptionableYes Debt/Eq0.00 EPS Q/Q16.60% Profit Margin- Rel Volume0.03 Prev Close2.24
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume10.15M Price2.22
Recom2.00 SMA20-14.62% SMA50-23.88% SMA200-8.65% Volume297,437 Change-0.89%
Jan-08-20Initiated Maxim Group Buy $2.50
Sep-09-21 08:05AM  
Sep-08-21 08:00AM  
Aug-13-21 08:05AM  
Jul-30-21 11:30AM  
Jul-28-21 02:00PM  
Jul-27-21 08:27AM  
Jul-26-21 07:00AM  
May-12-21 07:00AM  
May-10-21 08:30AM  
Mar-29-21 08:05AM  
Mar-17-21 08:00AM  
Mar-03-21 08:05AM  
Mar-01-21 09:49AM  
Feb-16-21 07:30AM  
Feb-01-21 09:47AM  
Jan-14-21 08:00AM  
Jan-05-21 08:05AM  
Dec-14-20 11:15AM  
Dec-10-20 07:42AM  
Dec-09-20 11:35AM  
Nov-13-20 08:00AM  
Nov-05-20 08:05AM  
Sep-09-20 08:35AM  
Sep-08-20 09:34AM  
Aug-13-20 07:05AM  
Jul-30-20 08:05AM  
Jul-01-20 08:05AM  
Jun-16-20 08:05AM  
Jun-08-20 08:35AM  
May-19-20 07:35AM  
May-14-20 04:05PM  
Apr-15-20 08:35AM  
Mar-27-20 09:00AM  
Feb-27-20 08:00AM  
Feb-26-20 08:00AM  
Feb-13-20 08:00AM  
Feb-11-20 08:05AM  
Jan-14-20 08:35AM  
Nov-15-19 08:30AM  
Oct-29-19 07:05AM  
Oct-18-19 11:21AM  
Oct-16-19 08:05AM  
Oct-08-19 08:30AM  
Jul-22-19 08:00AM  
Jul-17-19 08:45AM  
Jul-05-19 01:19PM  
Jun-24-19 09:08AM  
Jun-20-19 10:24AM  
May-14-19 07:42AM  
May-13-19 08:05AM  
May-02-19 07:05AM  
Apr-01-19 07:30AM  
Mar-05-19 09:27AM  
Mar-04-19 08:00AM  
Dec-04-18 02:57PM  
Aug-14-18 11:37PM  
Jun-25-18 07:30AM  
May-25-18 03:29PM  
Feb-05-18 08:09PM  
Jan-19-18 05:35PM  
Jan-02-18 04:29PM  
Dec-08-17 01:53PM  
Nov-30-17 07:35PM  
Nov-15-17 07:05AM  
Nov-02-17 08:05AM  
Oct-31-17 09:05AM  
Oct-04-17 01:16PM  
Oct-02-17 10:45AM  
Aug-23-17 08:05AM  
Aug-15-17 08:05AM  
Aug-14-17 05:00PM  
Jul-18-17 04:05PM  
Jun-26-17 08:35AM  
May-22-17 01:05PM  
May-16-17 07:00AM  
May-09-17 08:35AM  
May-01-17 08:30AM  
Apr-20-17 07:35AM  
Apr-04-17 07:30PM  
Apr-03-17 07:35AM  
Mar-31-17 05:10PM  
Mar-29-17 10:56AM  
Mar-27-17 08:05AM  
Mar-09-17 08:00AM  
Feb-27-17 03:49PM  
Jan-06-17 07:05AM  
Jan-04-17 05:27PM  
Jan-03-17 07:35AM  
Dec-20-16 07:16AM  
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. The company is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.